ScoreHaematology
International Prognostic Scoring System for myelodysplastic syndromes (IPSS, 1997)
Classifies myelodysplastic syndrome risk by marrow blasts, karyotype and number of cytopenias.
Updated 31 October 2026
When to use it
Adults with untreated primary MDS, especially when a trial or older protocol requires the original IPSS.
What it needs
- Bone marrow blasts
- Karyotype
- Number of cytopenias
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| < 0.5 | Low risk: median survival ≈ 5.7 years |
| 0.5 to < 1.5 | Intermediate-1: median survival ≈ 3.5 years |
| 1.5 to < 2.5 | Intermediate-2: median survival ≈ 1.2 years |
| ≥ 2.5 | High risk: median survival ≈ 0.4 years |
Practical tip
It has been superseded in practice by the IPSS-R (and IPSS-M); use it mainly for comparison with older studies.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
